Straits Times Index
3,257.83 -35.30 (-1.07%) Nikkei
37,900.90 -559.18 (-1.45%) Hang Seng
17,144.12 -57.15 (-0.33%) FTSE 100
8,040.38 -4.43 (-0.06%) Bitcoin USD
64,350.91 -2,442.80 (-3.66%) CMC Crypto 200
1,393.83 -30.27 (-2.12%)
Aquestive Therapeutics, Inc. (AQST)
After hours:
| Previous close | 4.2800 |
| Open | 4.2500 |
| Bid | 3.8700 x 400 |
| Ask | 3.9300 x 1000 |
| Day's range | 3.9000 - 4.2799 |
| 52-week range | 1.1900 - 6.2300 |
| Volume | |
| Avg. volume | 2,543,233 |
| Market cap | 385.063M |
| Beta (5Y monthly) | 2.91 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.1300 |
| Earnings date | 30 Apr 2024 - 06 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 9.00 |
GlobeNewswireAquestive Therapeutics to Present Crossover Study Data for Libervant™ (diazepam) Buccal Film at 76th Annual Meeting of the American Academy of Neurology
WARREN, N.J., April 12, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (the “Company” or “Aquestive”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced a poster presentation highlighting the crossover study for the Company’s product candidate, Libervant™ (diazepam) Buccal Film for treatment of children with epilepsy aged two to five, will be presented at the
ZacksAquestive Therapeutics (AQST) Ascends While Market Falls: Some Facts to Note
Aquestive Therapeutics (AQST) concluded the recent trading session at $4.14, signifying a +0.24% move from its prior day's close.
- GlobeNewswire
Aquestive Therapeutics Strengthens Board of Directors with Experienced Biotech Executive
Appoints Abigail “Abbey” Jenkins, a veteran biotech executive with over 20 years of experience in commercial leadership, to Board of DirectorsWARREN, N.J., April 01, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced the appointment of Abigail Jenkins to the Company’s Board of Direct
